Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris

Trial Profile

Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Betamethasone-dipropionate/calcipotriol (Primary) ; Betamethasone dipropionate; Calcipotriol
  • Indications Psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 30 Apr 2012 Actual patient number (677) added as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top